Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength (Buy)
Bristol-Myers: I'm Buying Post Earnings (StrongBuy)
(Earnings Call Insights) Bristol-Myers Squibb outlines $46B–$47.5B 2026 revenue target as growth portfolio nears 60% of sales driven by new product launches and pipeline catalysts
Why Bristol-Myers Squibb Remains Undervalued In 2025 (StrongBuy)
Bristol-Myers Squibb: Way Too Cheap At 7x P/E (StrongBuy)
Bristol-Myers Squibb Company Non-GAAP EPS of $1.63 beats by $0.11, revenue of $12.22B beats by $420M
(Earnings Call Insights) Bristol-Myers Squibb raises 2025 revenue guidance to $48B amid strong growth portfolio performance and pipeline advancements
Bristol-Myers Squibb_Earnings Champion Valued Like A Loser (StrongBuy)
Bristol-Myers Squibb_This High FCF Yield Is The Best Value In Healthcare (StrongBuy)
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics (Buy)
Bristol Myers Squibb_Value Emerges From Distress (Buy)
Bristol Myers Squibb_Buy This Deep Bargain Before The Market Wakes To Income (StrongBuy)
Bristol-Myers Squibb Why Q2 Results Signal A Turning Point (StrongBuy)
